Cutaneous T-Cell Lymphoma clinical study using Scarletred®Vision

PIQUR Therapeutics has kicked off the first human topical application of bimiralisib for patients with the rare disease “Cutaneous T-Cell Lymphoma”. The local tolerability of bimiralisib will be evaluated using multiple assessments, including daily evaluations of the treated lesions with Scarletred®Vision.

PIQUR expects to complete the treatment of the healthy volunteer cohort of this combined first-on-human / proof-of-concept study by fall 2019. Oral bimiralisib has already shown encouraging clinical activity and acceptable safety profile in Phase I/IIa studies in solid tumors and lymphomas.

Read more:
www.piqur.com/piqur-announces-first-human-topical-application-of-bimiralisib/
www.startupticker.ch/en/news/july-2019/piqur-kicks-off-first-human-trials-in-the-netherlands

Stay updated and follow SCARLETRED also here:
LinkedIn
Instagram
Twitter
Facebook